David Tink

David is a dual qualified (NSW and England & Wales) corporate lawyer with a strong track record advising on sophisticated corporate transactions, spanning equity capital markets, public and private M&A, and complex commercial arrangements in Australia and offshore.

David is highly regarded for his ability to lead complex corporate transactions with clarity and commercial focus. He advises a broad range of clients, including early-stage and growth companies, family / founder businesses and large listed and unlisted entities across multiple sectors in Australia and internationally.

Experience

David is highly experienced across equity capital markets transactions as well as private and public M&A. He advises on all aspects of the investment process, including entity and transaction structuring, term sheet negotiation, due diligence, seed and series funding, convertible notes and exit pathways (trade sales, dual tracks, IPOs and foreign listings).

David also regularly advises on Australia's corporate law and regulatory obligations, including the Corporations Act 2001 (Cth) and Australian Securities Exchange (ASX) Listing Rules. David also co-authored a chapter on prospectus content in the publication, 'ASX Entrepreneur’s Guide: Startup, Scaleup, IPO'.

David is dual qualified, having been admitted as a Solicitor of the Supreme Court of New South Wales and as a Solicitor of the Senior Courts of England and Wales. He has advised clients across a broad range of sectors with a particular focus on life sciences and biotechnology, energy and resources, professional services, technology, and construction and engineering.

David was previously a director in the corporate and commercial law team of a Big 4 consulting firm. Prior to that, he spent five years practising in the United Kingdom, where he specialised in corporate transactions (ECM and M&A) and general corporate and commercial advisory.

David’s national and international experience includes advising on transactions involving companies listed on all major global exchanges, including the ASX, Nasdaq, NYSE, TSX and LSE. He has led transactions across Australia, Asia, the Americas, Africa and Europe.

David's core areas of expertise include:

• Equity Capital Markets: Initial Public Offerings, re-compliance listings, foreign company listings (by way of issue of CHESS Depositary Interests) and dual listings, secondary placings, private capital raisings, convertible notes and other convertible securities and employee incentive plans
• Mergers and Acquisitions: private and public transactions on both the sell and buy side, due diligence, restructurings and business/asset sales
• Corporate law obligations including ASX Listing Rules advice, Corporations Act 2001 (Cth) compliance and director duties/obligations
• advising startups on all aspects of their business including capital raising and exit strategies.

Career highlights

David's recent career highlights include, advising:

Capital Markets and Public M&A

• Local Measure, a customer engagement technology company, on its 100% acquisition by a subsidiary of Zendesk, Inc. via a scheme of arrangement under the Corporations Act
• radiopharmaceuticals company, Clarity Pharmaceuticals on its $92m capital raising and admission to the Official List of the Australian Securities Exchange (ASX) (being the largest clinical stage biotech IPO in ASX's history)
• Clarity Pharmaceuticals on its $121 million placement and accelerated rights issue in 2024
• Clarity Pharmaceuticals on its $203 million placement in 2025
• NZX Listed BlackPearl Group on its capital raising and foreign exempt listing on ASX
• Airtree, a leading Australian venture capital investment group, on its Series A investment in the Australian ESG focused business, FairSupply
• RHI Magnesita, a London and Vienna listed global refractory business, on its multi-million dollar investments and collaboration arrangements with clean-tech start-up, MCI Carbon
• 3ME Technology group on its convertible note fundraising (including investment by ABGF and CEFC) and related matters
• various start-up entities on seed funding, convertible note raisings (including SAFE notes) and related matters
• various ASX-listed entities on other capital raisings and IPOs
• various AIM and LSE-listed entities on other capital raisings and IPOs.

Private M&A

• the founders and shareholders of Redback Boots on its majority sale to private equity firm, Ares
• the founders and shareholders of Smart Energy Group on its majority sale and partnership with Rinnai Australia
• the founders and shareholders of Allied Grain Group on its 100% sale to the Mitchells Group
• Armstrong Flooring Australia on the sale of its assets to the Cowes Bay Group in connection with a Delaware court-supervised competitive sale and bid process via a US Chapter XI insolvency proceeding
• the shareholders of the Connect Infrastructure group on the 100% sale of their business to ASX-listed entity, GenusPlus
• Automic Group on its acquisitions of Whittens and McKeough and CFO Innovation
• France based, Productlife Group, on its acquisition of leading pharmaceutical and medical device commercialisation company, Commercial Eyes
• Belgium based, Christeyns, on its acquisition of a majority stake in the chemicals focused True Brands group and associated shareholder arrangements
• the shareholders of a private app development company on the sale of its emergency response platform to Motorola, Inc
• the shareholders of the River Group Limited, a top six UK content marketing agency, on its sale to an affiliate of Sun Capital Partners LLP, a US private equity house.